Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,823 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,205 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05971628 | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma(RAPID-HCC) | not yet recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05970627 | Perioperative Chemotherapy Plus Toripalimab for Epstein-Barr Virus-associated Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma | not yet recruiting | Phase 2 | 30 | Yu jirenOTHER | 1 | Aug 1, 2023 |
| clinicaltrials |
| NCT05838053 | Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm | recruiting | — | 446 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05954117 | Chemotherapy in the Context of Esophageal and Gastroesophageal Junction Cancer Cachexia(CHIFMEOE) | not yet recruiting | N/A | 60 | University Hospital, Clermont-FerrandOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05954897 | Lenvatinib, Tislelizumab Combined With RALOX Regimen HAIC in Advanced Hepatocellular Carcinoma | recruiting | Phase 2 | 29 | Guangdong Provincial People's HospitalOTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05945407 | Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer | recruiting | N/A | 57 | Peking University People's HospitalOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT05941169 | Primary Metastatic Renal Cell Carcinoma Treated With Immunecheckpoint Inhibitors and Cytoreductive Nephrectomy(PrimerX) | not yet recruiting | N/A | 750 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 0 | Jul 12, 2023 | clinicaltrials |
| NCT05935189 | Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens(TIR-HCC) | recruiting | — | 500 | Nikomed Medical CenterNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05926726 | GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | recruiting | N/A | 12 | RenJi HospitalOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05916755 | Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform(PORTRAIT) | recruiting | — | 100 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05917431 | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | recruiting | Phase 2 | 39 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05895214 | Mesopancreas Study in Pancreatic Cancer(MESOPANC-01) | not yet recruiting | — | 500 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05887505 | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy | not yet recruiting | N/A | 120 | Taoyuan General HospitalOTHER_GOV | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05608200 | Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC | recruiting | Phase 3 | 427 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05870969 | Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)(dSEARCH) | recruiting | — | 20,000 | Ruijin HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT05862337 | Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence. | recruiting | Phase 3 | 480 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 17, 2023 | clinicaltrials |
| NCT05203120 | A National Phase II Study of Proton Therapy in Hepatocellular Carcinoma | recruiting | N/A | 50 | University of AarhusOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05813015 | Study of Comparing of With and Without Sequential Therapy of S-1 | recruiting | Phase 3 | 70 | Zhejiang UniversityOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT04047953 | Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | recruiting | N/A | 95 | Peking University Cancer Hospital & InstituteOTHER | 1 | Apr 5, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT00574327 | Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry | recruiting | — | 3,000 | Midwest Biomedical ResearchOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05218044 | Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ(DCIS) | recruiting | N/A | 30 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05752890 | A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma | not yet recruiting | — | 95 | National Taiwan University HospitalOTHER | 0 | Mar 3, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05738980 | Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3 | recruiting | N/A | 88 | Beijing HospitalOTHER_GOV | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05589207 | Predicting Model Based on Evidence-based Pathological Diagnose Criteria for RCC Tumor Thrombus With IVC Wall Invasion | recruiting | — | 232 | Peking University Third HospitalOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05602974 | Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study | not yet recruiting | N/A | 140 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05723718 | MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment(MOONRISE) | recruiting | — | 125 | Medical University of LublinOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05718492 | A Study of the Application of HAIC in Advanced HCC Previously Treated With ICIs and Antiangiogenic Agents | recruiting | N/A | 100 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05185505 | Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria | recruiting | Phase 4 | 24 | The Methodist Hospital Research InstituteOTHER | 1 | Feb 1, 2023 | clinicaltrials |
| NCT04625556 | Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome | recruiting | — | 3,000 | Yonsei UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT05433935 | Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas | recruiting | — | 5,000 | Zhejiang UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04442334 | The European NAFLD Registry | recruiting | — | 10,000 | Newcastle UniversityOTHER | 12 | Jan 6, 2023 | clinicaltrials |
| NCT05537922 | I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy | recruiting | — | 2,200 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 4 | Jan 6, 2023 | clinicaltrials |
| NCT05476432 | HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study | recruiting | Phase 3 | 300 | Sun Yat-sen UniversityOTHER | 1 | Dec 9, 2022 | clinicaltrials |
| NCT05642338 | A Multicenter Prospective Cohort Study Comparing Random Biopsies Versus Wide-Area Transepithelial Brush-Sampling (WATS) for Surveillance of Barrett's Esophagus, the WATS-EURO2 Study(WATSEURO2) | recruiting | — | 416 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Dec 8, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 2, 2023source: clinicaltrials